asthma
inflammatori
diseas
airway
characteris
variabl
airflow
obstruct
hyperrespons
one
frequent
chronic
diseas
young
adult
acut
exacerb
main
caus
morbid
healthcar
thu
prevent
futur
exacerb
key
goal
clinic
manag
patient
asthma
infect
respiratori
virus
particularli
rhinovirus
rv
common
trigger
asthma
exacerb
mechan
still
airway
epitheli
cell
cultur
ex
vivo
subject
produc
tslp
respons
viral
infect
asthmat
alarmin
stimul
helper
cell
innat
lymphoid
cell
produc
caus
recruit
eosinophil
airway
increas
mucu
secret
bronchial
hyperreact
class
switch
produc
ige
whether
eosinophil
inflamm
also
risk
factor
exacerb
unknown
demonstr
virus
activ
eosinophil
signal
toll
like
receptor
result
propag
reduc
rate
exacerb
whether
effect
predominantli
relat
viru
induc
exacerb
adjust
inhal
corticosteroid
ic
treatment
base
maintain
low
airway
eosinophil
effect
symptom
base
manag
reduc
exacerb
induct
process
sputum
feasibl
clinic
set
fraction
exhal
nitric
oxid
feno
produc
airway
epitheli
cell
stimul
associ
increas
risk
treatment
strategi
base
feno
reduc
rate
exacerb
show
conflict
trial
antibodi
shown
reduct
exacerb
rate
patient
high
periostin
protein
induc
receiv
treatment
ic
poor
asthma
knowledg
studi
evalu
associ
feno
sputum
eosinophil
risk
exacerb
specif
hypothesis
high
type
inflammatori
biomark
would
associ
higher
risk
asthma
exacerb
test
conduct
observ
prospect
cohort
studi
heterogen
popul
asthmat
examin
patient
baselin
subsequ
exacerb
stabl
asthma
patient
recruit
period
may
decemb
respiratori
outpati
clinic
bispebjerg
univers
hospit
copenhagen
denmark
patient
follow
least
month
specialist
outpati
clinic
enrol
studi
patient
examin
describ
follow
month
entri
date
time
patient
instruct
contact
studi
team
experienc
worsen
asthma
symptom
increas
use
surpass
usual
variat
patient
examin
within
hour
contact
studi
team
exacerb
defin
increas
symptom
requir
chang
medic
judg
attend
physician
line
atser
exacerb
manag
adjust
inhal
therapi
record
mildmoder
wherea
exacerb
requir
cours
oral
corticosteroid
oc
admiss
hospit
consid
addit
patient
instruct
perform
nasal
swab
home
experienc
symptom
common
examin
occas
local
scientif
ethic
committe
approv
studi
journal
nr
subject
inform
gave
written
consent
spirometri
easyon
ndd
switzerland
complet
accord
er
use
nhane
iii
skin
prick
test
soluprick
alk
denmark
complet
atopi
defin
posit
test
maximum
wheal
diamet
mm
least
one
ten
common
aeroallergen
grass
hous
dust
mite
birch
mugwort
dog
cat
hors
cladosporum
herbarum
alternaria
tenui
fraction
expiratori
nitric
oxid
feno
analys
nioxminor
aerocrin
solna
sweden
follow
recommend
er
use
mean
two
measur
ppb
feno
use
defin
patient
high
low
feno
sputum
induc
accord
er
guidelin
process
use
protocol
describ
pavord
et
differenti
cell
count
cytospin
obtain
cell
sputum
eosinophil
appli
defin
high
low
sputum
eosinophil
report
correspond
percentil
sputum
eosinophil
healthi
blood
sampl
assess
hospit
clinic
servic
includ
full
white
blood
cell
differenti
count
measur
protein
crp
well
total
ige
coba
roch
basel
switzerland
asthma
control
assess
asthma
control
questionnair
acq
nasal
swab
copan
italia
use
sampl
nasal
fluid
test
use
tandem
multiplex
pcr
assay
detect
comprehens
rang
respiratori
virus
human
adenoviru
speci
human
bocaviru
coronavirus
influenza
virus
b
c
parainfluenza
virus
ki
wu
polyomavirus
respiratori
syncyti
viru
type
b
human
rv
detect
pcr
direct
sequenc
genom
rv
product
identifi
speci
level
sequenc
bp
product
align
known
rv
sequenc
use
clustalx
bispebjerg
hospit
laboratori
complet
bacteri
cultur
spontan
expector
gather
exacerb
data
analys
spss
version
ibm
spss
armonk
ny
usa
normal
distribut
data
report
deviat
analys
use
student
test
continu
variabl
test
categor
variabl
variabl
report
geometr
mean
gm
ci
distribut
data
eg
cell
count
report
median
rang
comparison
made
use
test
assess
abil
baselin
characterist
predict
risk
exacerb
proport
hazard
model
cox
regress
use
adjust
predefin
potenti
confound
exacerb
risk
includ
ic
dose
smoke
statu
acq
score
predict
forc
expiratori
volum
first
second
expir
baselin
inflammatori
marker
examin
feno
sputum
eosinophil
highli
correl
previou
studi
data
marker
test
separ
avoid
multicollinear
analys
consid
signific
total
patient
approach
patient
agre
particip
figur
ic
taken
patient
remain
use
short
act
alon
recruit
patient
feno
elev
baselin
ppb
among
patient
abl
produc
valid
sputum
sampl
patient
sputum
eosinophil
eight
patient
high
feno
high
sputum
eosinophil
clinic
characterist
studi
subject
describ
tabl
period
particip
develop
exacerb
figur
patient
one
exacerb
studi
period
patient
exacerb
respiratori
viru
detect
exacerb
predominantli
rv
human
coronaviru
hcov
figur
cours
oral
corticosteroid
prescrib
patient
exacerb
wherea
remain
manag
temporari
increas
ic
alon
patient
requir
admiss
hospit
two
patient
treat
antibiot
suspect
bacteri
pneumonia
although
bacteri
cultur
later
found
neg
patient
characterist
includ
age
sex
smoke
statu
differ
exacerb
tabl
exacerb
group
mean
feno
baselin
higher
ppb
ci
compar
group
ppb
ci
exacerb
patient
also
higher
acq
score
baselin
compar
patient
trend
lower
preval
atopi
exacerb
group
vs
lung
function
ic
dose
sputum
blood
differenti
cell
count
similar
group
tabl
patient
high
sputum
eosinophil
baselin
five
patient
exacerb
compar
eosinophil
low
group
six
patient
exacerb
among
patient
high
feno
baselin
six
patient
experienc
exacerb
compar
feno
low
group
nine
patient
exacerb
unadjust
test
show
patient
high
feno
shorter
time
exacerb
low
feno
day
ci
vs
day
ci
specif
shorter
time
exacerb
day
ci
vs
day
ci
respect
similar
differ
time
exacerb
seen
compar
patient
base
higher
vs
lower
acq
score
patient
acq
score
day
ci
exacerb
vs
day
ci
acq
score
howev
differ
time
exacerb
high
vs
low
acq
score
day
ci
vs
day
ci
respect
unadjust
analys
patient
without
sputum
eosinophilia
similar
time
exacerb
figur
proport
hazard
model
construct
adjust
known
determin
exacerb
risk
amount
ic
usag
current
smoke
acq
score
predict
baselin
demograph
variabl
sex
age
bmi
univari
analys
includ
model
inflammatori
marker
assess
separ
predict
risk
exacerb
summaris
tabl
patient
group
analysi
high
feno
baselin
increas
risk
subsequ
exacerb
hr
ci
increas
risk
exacerb
hr
ci
compar
low
feno
high
sputum
eosinophil
also
increas
risk
exacerb
hr
ci
particularli
exacerb
hr
ci
compar
low
eosinophil
tabl
word
patient
feno
ppb
increas
risk
exacerb
compar
patient
lower
feno
patient
sputum
eosinophil
increas
risk
compar
patient
lower
eosinophil
percentag
diseas
control
lung
function
ic
use
tobacco
consumpt
baselin
kept
potenti
relev
risk
factor
relat
type
inflamm
also
examin
adjust
potenti
confound
atop
statu
blood
eosinophil
cellsl
total
ige
iu
none
variabl
predict
risk
exacerb
tabl
total
patient
sent
swab
symptom
common
cold
without
sign
exacerb
detect
respiratori
viru
enteroviru
sputum
eosinophil
mean
feno
baselin
differ
exacerb
cold
experienc
cold
exacerb
tabl
howev
proport
patient
feno
significantli
differ
lowest
cold
highest
exacerb
tabl
patient
exacerb
higher
feno
exacerb
gm
ppb
ci
gm
ppb
ci
studi
feno
ppb
sputum
eosinophil
associ
increas
risk
develop
asthma
exacerb
furthermor
patient
develop
exacerb
like
feno
ppb
baselin
patient
report
upper
respiratori
symptom
respiratori
viral
infect
feno
sputum
eosinophil
associ
higher
risk
exacerb
knowledg
first
studi
assess
type
airway
inflamm
risk
factor
specif
asthma
exacerb
rate
exacerb
lower
previou
studi
similar
design
major
exacerb
viru
induc
patient
exacerb
rule
associ
type
inflamm
baselin
risk
exacerb
group
inde
given
similar
proport
vs
exacerb
low
high
group
type
marker
seem
plausibl
effect
limit
exacerb
nevertheless
identifi
associ
type
inflamm
exacerb
suggest
area
warrant
investig
limit
includ
lack
surveil
patient
eg
peak
flow
monitor
henc
registr
exacerb
depend
patient
contact
research
unit
experienc
symptom
surpass
daili
variat
howev
patient
regularli
contact
phone
remind
particip
studi
final
possibl
result
might
differ
cohort
sever
asthmat
higher
exacerb
rate
potenti
sever
exacerb
strength
studi
prospect
follow
heterogen
popul
asthmat
repres
everyday
clinic
scenario
experienc
respiratori
clinician
causal
role
type
inflamm
asthma
exacerb
support
studi
antibodi
inhibit
signal
phase
ii
iii
studi
monoclon
antibodi
mepolizumab
shown
reduct
exacerb
frequenc
approxim
effect
lost
within
month
treatment
likewis
treatment
antibodi
lebrikizumab
reduc
rate
exacerb
moder
sever
asthmat
elev
whether
exacerb
prevent
strategi
predominantli
viral
yet
report
data
suggest
effect
exacerb
like
none
particip
develop
upper
respiratori
tract
symptom
feno
ppb
develop
exacerb
elev
feno
line
find
high
feno
increas
risk
exacerb
suggest
patient
type
inflamm
resist
lower
airway
involv
infect
common
respiratori
virus
howev
exploratori
outcom
number
low
feno
level
differ
analys
continu
variabl
therefor
need
explor
larger
studi
synergist
effect
allerg
sensitis
viral
infect
risk
hospit
admiss
describ
studi
observ
increas
risk
exacerb
viral
patient
sensitis
common
aeroallergen
indic
associ
might
pronounc
paediatr
popul
studi
found
high
affin
result
blunt
interferon
respons
turn
associ
ineffect
viral
pronounc
asthma
furthermor
antibodi
omalizumab
shown
elimin
peak
exacerb
larg
cohort
asthmat
children
suggest
reduct
taken
togeth
indic
high
ige
might
play
role
asthma
exacerb
howev
studi
high
ige
associ
increas
risk
exacerb
advent
antibodi
treatment
option
come
year
widespread
intent
enhanc
personalis
asthma
manag
tailor
medic
choic
dosag
accord
inflammatori
phenotyp
treatment
like
prevent
exacerb
given
respiratori
virus
major
trigger
exacerb
understand
pathway
airway
inflamm
influenc
risk
exacerb
critic
step
understand
optimis
use
antibodi
therapi
achiev
best
individu
patient
outcom
conclus
shown
high
feno
sputum
eosinophil
baselin
risk
factor
exacerb
set
confirm
larger
studi
could
implic
risk
assess
asthma
patient
author
declar
conflict
interest
